Remedy for cancer with reduced sensitivity to molecular targeted drugs and pharmaceutical composition for enhancing sensitivity to molecular targeted drugs

摘要

A pharmaceutical composition for enhancing the sensitivity of a cancer that is resistant to a molecular target drug such as gefitinib or erlotinib, and an effective cancer therapeutic drug for a cancer that is resistant to a molecular target drug such as gefitinib or erlotinib provide. A pharmaceutical composition containing an HGF-MET receptor system inhibitor can enhance the sensitivity of a cancer that exhibits resistance to a molecular target drug to the molecular target drug. In addition, a cancer therapeutic drug comprising a combination of a molecular target drug and an HGF-MET receptor system inhibitor is effective against cancer that exhibits resistance to the molecular target drug.